{"classes":[{"categories":[{"measurements":[{"comment":"Not enough responses to calculate upper limit of 95% CI","groupId":"OG001","lowerLimit":"1.41","upperLimit":"NA","value":"5.49"},{"comment":"Not enough responses to calculate a median or upper limit of 95% CI","groupId":"OG002","lowerLimit":"1.45","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"description":"DOR was defined as number of months between first objective response to progressive disease or death (due to any cause), whichever occurred first.\n\nKaplan-Meier methods were used to estimate the distribution of DOR. The median and corresponding two-sided 95% confidence intervals were calculated.","dispersionType":"95% Confidence Interval","groups":[{"description":"28 day continuous intravenous infusion of AMG 420 200 µg/day followed by a 2 week treatment-free interval, until progressive disease (PD) or relapse as defined by International Myeloma Working Group (IMWG) response criteria, unacceptable safety events, next anti-multiple myeloma treatment, or other reason for permanent treatment discontinuation","id":"OG000","title":"AMG 420 200 µg/Day"},{"description":"28 day continuous intravenous infusion of AMG 420 400 µg/day followed by a 2 week treatment-free interval, until PD or relapse as defined by IMWG response criteria, unacceptable safety events, next anti-multiple myeloma treatment, or other reason for permanent treatment discontinuation","id":"OG001","title":"AMG 420 400 µg/Day"},{"description":"28 day continuous intravenous infusion of AMG 420 600 µg/day followed by a 2 week treatment-free interval, until PD or relapse as defined by IMWG response criteria, unacceptable safety events, next anti-multiple myeloma treatment, or other reason for permanent treatment discontinuation","id":"OG002","title":"AMG 420 600 µg/Day"}],"paramType":"MEDIAN","populationDescription":"Safety analysis set includes all participants who enrolled and received at least 1 dose of AMG 420.\n\nDOR was only calculated for participants who experienced a best overall response of partial response or better.","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Months"}